Precision Oncology in Hematological Malignancies: Pharmacogenomics for Enhanced Therapeutic Efficacy and Diminished Toxicity
Hematological malignancies, including acute and chronic leukemias, lymphomas, and multiple myeloma, continue to present clinicians with diverse responses to traditional chemotherapies and kinase inhibitors due to myelosuppression, off-target effects, and acquired resistance. Pharmacogenomics lets you choose the right d...